Trastuzumab treatment improves brain metastasis outcomes through control and durable prolongation of systemic extracranial disease in HER2-overexpressing breast cancer patients

British Journal of Cancer

Volumn 100, Issue 6, 2009, Pages 894-900

  Park, Y H ^a   Park, M J ^a   Ji, S H ^a   Yi, S Y ^a   Lim, D H ^a   Nam, D H ^a   Lee, J I ^a   Park, W ^a   Choi, D H ^a   Huh, S J ^a   Ahn, J S ^a   Kang, W K ^a   Park, K ^a   Im, Y H ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Brain metastasis; Extracranial disease control; HER2 overexpressing breast cancer; Trastuzumab

Indexed keywords

ANTHRACYCLINE; CAPECITABINE; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GEMCITABINE; LAPATINIB; NAVELBINE; TAXANE DERIVATIVE; TRASTUZUMAB;

ADULT; AGED; ARTICLE; BRAIN METASTASIS; BRAIN RADIATION; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER PATIENT; CANCER STAGING; CANCER THERAPY; CONTROL GROUP; CONTROLLED STUDY; GAMMA KNIFE RADIOSURGERY; HUMAN; MAJOR CLINICAL STUDY; MEDICAL RECORD; OUTCOME ASSESSMENT; PALLIATIVE THERAPY; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; SINGLE DRUG DOSE; STEREOTACTIC RADIOSURGERY;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BLOOD-BRAIN BARRIER; BRAIN NEOPLASMS; BREAST NEOPLASMS; FEMALE; HUMANS; LOGISTIC MODELS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; RECEPTOR, ERBB-2;

EID: 62549135630     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6604941     Document Type: Article

References (34)

1. Altaha R, Crowell E, Ducatman B (2004) Risk of brain metastases in HER2/neu-positive breast cancer. J Clin Oncol 22: 47s
2. Bartsch R, Rottenfusser A, Wenzel C, Dieckmann K, Pluschnig U, Altorjai G, Rudas M, Mader RM, Poetter R, Zielinski CC, Steger GG (2007) Trastuzumab prolongs overall survival in patients with brain metastases from HER2 positive breast cancer. J Neurooncol 85: 311-317
3. Bendell JC, Domchek SM, Burstein HJ, Harris L, Younger J, Kuter I, Bunnell C, Rue M, Gelman R, Winer E (2003) Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 97: 2972-2977
4. Boss JS, Fletcher JA, Linette GP (2003) The HER-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. Oncologist 8: 307-325
5. Boyle P, Ferlay J (2005) Cancer incidence and mortality in Europe, 2004. Ann Oncol 16: 481-488
6. Clayton AJ, Danson S, Jolly S, Ryder WD, Burt PA, Stewart AL, Wilkinson PM, Welch RS, Magee B, Wilson G, Howell A, Wardley AM (2004) Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer. Br J Cancer 91: 639-643
7. Dawood S, Broglio K, Esteva FJ, Ibrahim NK, Kau SW, Islam R, Aldape KD, Yu TK, Hortobagyi GN, Gonzalez-Angulo AM (2008) Defining prognosis for women with breast cancer and CNS metastases by HER2 status. Ann Oncol 19: 1242-1248
8. DiStefano A, Yong Yap Y, Hortobagyi GN, Blumenschein GR (1979) The natural history of breast cancer patients with brain metastases. Cancer 44: 1913-1918
9. Engel J, EcKel R, Aydemir U, Aydemir S, Kerr J, Schlesinger-Raab A, Dirschedl P, Hölzel D (2003) Determinants and prognoses of locoregional and distant progression in breast cancer. Int J Radiat Oncol Biol Phys 55: 1186-1195
10. Gori S, Rimondini S, De Angelis V, Colozza M, Bisagni G, Moretti G, Sidoni A, Basurto C, Aristei C, Anastasi P, Crinò L (2007) Central nervous system metastases in HER2-positive metastatic breast cancer patients treated with trastuzumab: incidence, survival, and risk factors. Oncologist 12: 766-773
11. Herrero A, Grandez R, Puertolas T (2004) High incidence of brain metastases at the time of death in women with metastatic breast cancer treated with trastuzumab. J Clin Oncol 22(suppl 14): 765s
12. Kallioniemi OP, Holli K, Visakorpi T, Koivula T, Helin HH, Isola JJ (1991) Association of c-erbB-2 protein over-expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long-term survival in breast cancer. Int J Cancer 4: 650-655
13. Kirsch DG, Ledezma CJ, Mathews CS, Bhan AK, Ancukiewicz M, Hochberg FH, Loeffler JS (2005) Survival after brain metastases from breast cancer in the trastuzumab era. J Clin Oncol 23: 2114-2116
14. Korea National Statistical Office (2007) Death rate statistics of Korea, 2005. Korea National Statistical Office: Korea
15. Lin NU, Bellon JR, Winer EP (2004) CNS metastases in breast cancer. J Clin Oncol 22: 3608-3617
16. Lin NU, Winer EP (2007) Brain metastases: the HER2 paradigm. Clin Cancer Res 13: 1648-1655
17. Mollick JA, Carlson RW (2004) Rational surveillance programs for early stage breast cancer patients after primary treatment. Breast Dis 21: 47-54
18. Paik S, Hazan R, Fisher ER, Sass RE, Fisher B, Redmond C, Schlessinger J, Lippman ME, King CR (1990) Pathologic finding from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein expression in primary breast cancer. J Clin Oncol 8: 103-112
19. Park BB, Uhm JE, Cho EY, Choi YL, Ji SH, Nam DH, Lee JI, Park W, Huh SJ, Park YH, Ahn JS, Im YH (2009) Prognostic factor analysis in patients with brain metastases from breast cancer: how can we improve the treatment outcomes? Cancer Chemother Pharmacol 63(4): 627-633
20. Patanaphan V, Salazar OM, Risco R (1988) Breast cancer: metastatic pattern and their prognosis. South Med J 81: 1109-1112
21. Pegram MD, Konecny GE, Callaghan C, Beryt M, Pietras R, Slamon DJ (2004) Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J Natl Cancer Inst 96: 739-749
22. Pestalozzi BC, Brignoli S (2000) Trastuzumab in CSF. J Clin Oncol 18: 2349-2351
23. Pestalozzi BC, Zahrieh D, Price KN, Holmberg SB, Lindtner J, Collins J, Crivellari D, Fey MF, Murray E, Pagani O, Simoncini E, Castiglione-Gertsch M, Gelber RD, Coates AS, Goldhirsch A, International Breast Cancer Study Group (IBCSG) (2006) Identifying breast cancer patients at risk for central nervous system (CNS) metastases in trials of the international breast cancer study group (IBCSG). Ann Oncol 17: 935-944
24. Ross JS, Fletcher JA, Linette GP, Stec J, Clark E, Ayers M, Symmans WF, Pusztai L, Bloom KJ (2003) The Her-2/neu gene and protein in breast cancer. Oncologist 8: 307-325
25. Slamon DJ, Clark GM, Wong SD, Levin WJ, Ullrich A, McGuire WL (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER2/neu oncogene. Science 235: 177-182
26. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L (2001) Use of chemotherapy plus a monoclonal antibody HER2 for metastatic breast cancer that overexpress HER2. N Engl J Med 344: 783-792
27. Smigal C, Jemal A, Ward E, Cokkinides V, Smith R, Howe HL, Thun M (2006) Trends in breast cancer by race and ethnicity: update 2006. CA Cancer J Clin 56: 168-183
28. Souglakos J, Vamvakas L, Apostolaki S, Perraki M, Saridaki Z, Kazakou I, Pallis A, Kouroussis C, Androulakis N, Millaki G, Mavroudis D, Georgoulias V (2006) Central nervous system relapse in patients with breast cancer is associated with advanced stages, with the presence of circulating occult tumor cells and with the HER2/neu status. Breast Cancer Res 8: R36
29. Stemmler HJ, Heinemann V (2008) Central nervous system metastases in HER2-overexpressing metastatic breast cancer: a treatment challenge. Oncologist 13: 739-750
30. Stemmler HJ, Kahlert S, Siekiera W, Untch M, Heinrich B, Heinemann V (2006) Characteristics of patients with brain metastases receiving trastuzumab for HER2 overexpressing metastatic breast cancer. Breast 15: 219-225
31. Stemmler HJ, Schmitt M, Willems A, Bernhard H, Harbeck N, Heinemann V (2007) Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impaired blood-brain barrier. Anticancer Drugs 18: 23-28
32. Tham YL, Sexton K, Kramer R, Hilsenbeck S, Elledge R (2006) Primary breast cancer phenotypes associated with propensity for central nervous system metastases. Cancer 107: 696-704
33. Tsukada Y, Fouad A, Pickren JW, Lane WW (1983) Central nervous system metastasis from breast carcinoma. Autopsy study. Cancer 52: 2349-2354
34. Yau T, Swanton C, Chua S, Sue A, Walsh G, Rostom A, Johnston SR, O'Brien ME, Smith IE (2006) Incidence, pattern, and timing of brain metastases among patients with advanced breast cancer treated with trastuzumab. Acta Oncol 45: 196-201